40.02 +0.09 (0.23%)
Pre-Market: 5:32AM EDT
|Bid||40.03 x 1000|
|Ask||40.02 x 3200|
|Day's Range||39.81 - 40.19|
|52 Week Range||36.41 - 42.36|
|Beta (3Y Monthly)||0.54|
|PE Ratio (TTM)||40.25|
|Earnings Date||Feb 1, 2017 - Feb 6, 2017|
|Forward Dividend & Yield||2.39 (5.71%)|
|1y Target Est||44.33|
The FTSE 100 is an index that includes the top 100 companies from the London Stock Exchange. They are ranked by their market capitalization. However, market cap may not be an investor’s only interest in a stock.
HAMILTON, Mont. (AP) — Drugmaker GlaxoSmithKline has announced $100 million of new investment in its manufacturing site in Montana.
A large-scale pilot of a vaccine that could prevent some of the 250,000 child deaths each year from malaria has begun in Malawi after successful clinical trials. The vaccine — called RTS,S — acts against the most deadly malaria parasite and has been in development by GlaxoSmithKline for more than three decades. According to the World Health Organization, it is the first vaccine to demonstrate it can significantly reduce cases of malaria in children.
Alexion's (ALXN) first-quarter 2019 results are likely to gain on solid performance of lead drug, Soliris. Investors will also focus on updates on pipeline candidates.
Investors are looking forward to Revlimid's performance and updates on the impending acquisition agreement with Bristol-Myers, when Celgene Corporation (CELG) reports Q1 results.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Performance of Opdivo and the impending acquisition of Celgene Corporation will be key areas of focus for the investors, when Bristol-Myers (BMY) reports first-quarter results.
The changes are part of a new approach to R&D; prioritizing innovation and moving towards delivering a pipeline of medicines with a focus on immunology.
Although sales of Clovis' (CLVS) Rubraca improved in the fourth quarter of 2018, the drug may face significant competition going forward. Clovis is also evaluating Rubrca for other cancer indications.
A recent FDA approval has one Triangle pharmaceutical company going head to head with the likes Pharma giants such as GSK – in an multi-billion dollar industry company officials believe they have the edge in.
Emergent (EBS) posts interim data from the phase II study on its chikungunya vaccine, CHIKV-VLP. The candidate generates positive immune response against the chikungunya virus.
Axsome's (AXSM) mid-stage candidate, AXS-05, achieves the primary endpoint in a phase II study as a smoking cessation treatment. Shares rise.
Clovis Oncology (CLVS) halts mid-stage bladder cancer study evaluating Rubraca monotherapy. It is unlikely to provide meaningful clinical benefit as reviewed by an independent data monitoring committee.
(Reuters) - Britain's main index lost ground on Monday as miners and oil majors fell, more than offsetting gains in bank stocks. The FTSE 100 was 0.2 percent lower, lagging its European and Asian counterparts, ...
Glaxo (GSK) gets FDA approval for a new HIV medicine, Dovato. AstraZeneca (AZN)/Merck's (MRK) Lynparza gets approval in EU for metastatic breast cancer.
Novartis' (NVS) Sandoz signs an agreement with Japanese company, Shionogi, to commercialize constipation drug in key European markets.
AstraZeneca (AZN) and Merck gain an EU approval for Lynparza as a monotherapy for treating HER2-negative locally-advanced/metastatic breast cancer.
Gilead Sciences stock has long been a leader in the HIV space, so even though stock is off after a competing treatment’s approval, RBC Capital Markets doesn’t think investors should give up just yet.